After this afternoon's -3.0% drop to $58.62 per share, Halozyme Therapeutics might just keep moving past its target price of $61.56. With an average analyst rating of buy, and target prices from $48.0 to $75.0, the stock's next move is anyone's guess.
The stock has an above average percentage of its shares sold short at 10.3%, and a short ratio of 7.52. Since 1.08% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 98.3% of Halozyme Therapeutics's shares being owned by this investor type.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Blackrock Inc. | 14% | 17,619,937 | $1,032,968,806 |
| 2024-06-30 | Vanguard Group Inc | 10% | 12,881,459 | $755,175,533 |
| 2024-06-30 | State Street Corporation | 5% | 5,814,207 | $340,857,885 |
| 2024-06-30 | Snyder Capital Management, LP | 3% | 4,039,912 | $236,839,841 |
| 2024-06-30 | Artisan Partners Limited Partnership | 3% | 3,717,264 | $217,924,602 |
| 2024-06-30 | Alliancebernstein L.P. | 3% | 3,549,075 | $208,064,521 |
| 2024-06-30 | Macquarie Group Limited | 2% | 3,077,527 | $180,420,020 |
| 2024-06-30 | JP Morgan Chase & Company | 2% | 3,071,854 | $180,087,440 |
| 2024-06-30 | Geode Capital Management, LLC | 2% | 3,029,230 | $177,588,608 |
| 2024-06-30 | TD Asset Management, Inc | 2% | 2,365,983 | $138,705,753 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Halozyme Therapeutics.
